RESPIRATORY SYNCYTIAL VIRUS (RSV)

This study will test a new RSV vaccine in 60 adults aged 20 and older. The goal is to understand how the vaccine triggers the immune system, including antibody and T-cell responses. Researchers hope this will lead to better RSV vaccines in the future.

This early-stage study tests a new vaccine (MKK900) against respiratory syncytial virus (RSV) in 120 healthy women aged 18 to 49. The main goal is to check if the vaccine is safe and triggers a strong immune response. Participants will receive either the new vaccine or an active …

This study will check how well a new RSV vaccine (RSVpreF) works when given to pregnant women in Brazil. Researchers will follow 5,000 infants up to 6 months old who are hospitalized or seen in clinics for respiratory illness. By comparing babies whose mothers got the vaccine to …

This study tests an experimental oral drug called zelicapavir in 150 children aged 28 days to 36 months who have respiratory syncytial virus (RSV) infection. Half receive the drug, half receive a placebo. The goal is to see if zelicapavir speeds up recovery from RSV symptoms and …

This study tests a new medicine called SIBP-A16 to see if it can safely prevent RSV in infants under 1 year old, including those born early. About 36 babies will receive either the new drug, a placebo, or an existing RSV drug. The main goal is to check for side effects and how th…

This study tests whether a single dose of nirsevimab, an RSV-specific antibody, can prevent respiratory infections in Aboriginal and Torres Strait Islander children aged 6 months in Australia's Northern Territory. One thousand infants will be randomly assigned to receive the anti…